REG - IntelliAM AI PLC - Directorate Change

abrdn Equity Income TrustAnnouncement

Today 08:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250502:nRSB1508Ha&default-theme=true

RNS Number : 1508H  IntelliAM AI PLC  02 May 2025

 

2 May 2025

 

IntelliAM AI Plc

('IntelliAM' or the 'Company')

Board Appointment

 

IntelliAM AI plc (AQSE: INT), the software company leveraging the power of
AI and machine learning in the manufacturing industry, announces the
appointment of Dr Keith Harris to the board as non-executive director and
Chairman-elect. Dr Harris will become Non-Executive Chairman on 1 July 2025.

Dr Harris is a highly regarded investment banker and corporate strategist with
over 35 years of experience advising on complex cross-border M&A, equity
and debt capital markets transactions, and corporate leadership. He has held
senior roles at Morgan Grenfell, Drexel Burnham, and served as Chief Executive
of HSBC Investment Bank. Dr Harris was also the principal owner and Chairman
of Seymour Pierce Holdings and has held a number of high-profile board
positions, including Chairman of Wembley National Stadium, and the Football
League.

He currently serves as Chairman of NASDAQ-listed gene therapy company MeiraGTx
and Executive Chairman of Global Connectivity Plc, quoted on AQSE.

Strategic Appointment to Support Next Growth Phase

This appointment comes at a time of increasing momentum for IntelliAM, as the
Company scales its AI-powered solutions across global industrial sectors. Dr
Harris's deep expertise in capital markets will be instrumental as IntelliAM
accelerates its growth and explores strategic opportunities in the UK and
internationally.

Tom Clayton, CEO of IntelliAM, commented:

"We are delighted to welcome Keith to the board. His extraordinary track
record in capital markets and board leadership will bring enormous value to
IntelliAM as we deepen our relationships with institutional investors and
pursue our strategic growth initiatives."

Dr Harris, Chairman-elect, said:

"IntelliAM is delivering real transformation in a vital sector through the
intelligent application of AI. I look forward to working with Tom and the
board to support the company's ambitions and help realise its significant
market potential."

Trading Update and Full-Year Results

The Company will publish a trading update for the year ended 31 March 2025 on
12 May 2025, followed by its audited full-year results in July 2025.

Disclosure of information required under Rule 4.9 of the Aquis Growth Market
Access Rulebook

Keith Reginald Harris is, or has been in the last five years, a director of
the following companies:

 Current Directorships                       Former Directorships in the last five years
 MeiraGTx Holdings Plc                       Good Life Plus (previously Semper Fortis Esports Limited)
 Global Connectivity Plc                     Yesod Bio-Sciences Limited
 Keith Harris & Associates Limited           Deneng Limited (previously As Sports Management Limited)
 Core Ldn Limited                             vTv Therapeutics Inc
 Voneus Limited
 Rural Broadband Solutions Holdings Limited
 TCRK Limited
 Cherwell Films LLP

Dr Harris has no direct or indirect interest in the Company's issued share
capital.

Dr Harris is a London-based investment banker and financier with
a 25-year career as a senior corporate finance and takeover advisor. Since
1999, Dr. Harris has been the chairman of Keith Harris & Associates, a
sports consulting firm. Dr Harris previously served as Chief Executive
Officer of HSBC Investment Bank from 1994 to 1999.

 

Dr Harris received a BSc in business and economics from the University of
Bradford and a PhD in Economics from the University of Surrey.

 

Dr Harris served as a director of Seymour Pierce Holdings Limited, a
non-operating holding company, at the time administrators were appointed in
February 2013. The appointment followed the sale of its sole wholly-owned
asset, Seymour Pierce Limited, a company in which Dr Harris held no
directorial position.

 

Except as set out above, there is no further information regarding Dr Harris
that is required to be disclosed pursuant to Rule 4.9 of the AQSE Growth
Market Access Rulebook.

 

Our board of directors believes that Dr Harris' financial knowledge and
experience qualifies him to serve as a member of our board of directors.

 

 Enquiries:

 IntelliAM AI plc                                     +44 114 299 5007

 Tom Clayton, Chief Executive Officer

 Daud Khan, Chief Financial Officer

 Oberon Capital - AQSE Corporate Adviser and Broker   +44 203 179 5300

 Adam Pollock

 Mike Seabrook

 Jessica Cave

 Square1 Consulting - Financial PR                    +44 207 929 5599

 David Bick                                           +44 7831 381201

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NEXFLFIAEIILIIE